What is the recommended strategy for patients on hormone replacement therapy (HRT) at risk for osteoporosis?

The recommended strategy for patients on hormone replacement therapy (HRT) at risk for osteoporosis is to use the lowest dose for the shortest duration that effectively alleviates symptoms. This approach minimizes the potential risks associated with long-term use of HRT, which can include an increased risk of certain cancers and cardiovascular issues.

Using HRT at the lowest effective dose helps in managing menopausal symptoms while also supporting bone health. Women who are at risk for osteoporosis need to balance the benefits of HRT, such as the preservation of bone density, against the risks that can arise from prolonged use of hormone therapy. Therefore, the emphasis is on careful monitoring and assessment of individual patient needs to find the optimal balance between symptom relief and safety.

The shortest duration of therapy that achieves symptom relief is also advocated, as the risk of adverse effects tends to increase with longer exposure to HRT. This strategy aligns with best practices in managing risks associated with osteoporosis and hormone replacement therapy, aiming to protect patient health without unnecessary complications.